Water Street Completes Dual Acquisitions to Continue Building Life Sciences Commercialisation Services Platform
Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry, announced today that it has completed two acquisitions to build a leading global life sciences’ commercialisation services platform. The health care firm has acquired Alliance Life Sciences (Alliance) and Health Strategies Group. Water Street will bring the two companies together with The Access Group, a business it acquired last year, under a global enterprise that will offer life sciences companies a suite of commercialisation services to support them with bringing new therapies to market, and gaining and sustaining market access and share.
“We are excited to be at the forefront of helping life sciences firms develop, manage and deliver new outcomes-based therapies that address specific patient populations and diseases,” said Jim Lang, an executive adviser with Water Street who will serve as executive chairman of the newly combined enterprise. “By bringing these two market-leading companies together with The Access Group, we are taking the next step toward building a global leader that will offer life sciences companies an integrated portfolio of solutions to help them bring the right therapies to the right patients at the right value.”
Alliance, founded in 2008, specialises in maximising revenue and optimising pricing for its customers. The firm offers a broad array of global pricing analytic tools and data, outsourced contract and revenue management services, including business process outsourcing, and digital marketing operational services.
Founded in 1992, Health Strategies Group is the leader in market access intelligence and customised research for pharmaceutical and biotech professionals. Its team of analysts dissects trends and identifies opportunities to help companies optimise their product access and distribution.
Emmanuel Doe, CEO, Alliance, stated: “Together with Health Strategies Group and The Access Group, we will offer our customers a deeper and more extensive portfolio of next-generation solutions that address the entire spectrum of their commercial needs. As one entity, we will have a greater impact on aligning outcomes among patients, caregivers, physicians and payers for pharmaceutical and medical device products.”
Alan Crowther, president of global markets, Alliance, added: “Our clients are working incredibly fast and hard to bring new and life-changing therapies to market. Building this new platform with Water Street enables us to combine our software development, data management and business process outsourcing capabilities with new services that will accelerate getting these therapies to the patients who need them.”
Water Street’s new global enterprise will work with life sciences companies to introduce new therapies and optimise existing therapies to targeted patient populations through the following suite of solutions:
- Strategic and Advisory Consulting Services
- Agency Implementation and Execution
- Research, Data and Analytics Products
- Turnkey Outsourced Operations
Alliance, Health Strategies Group and The Access Group will continue to operate under their current names and leadership teams. The executives of each company will report to the holding company’s board of directors spearheaded by Executive Chairman Jim Lang.
Financial details of the acquisitions are not being disclosed.
Alliance Life Sciences is a global innovator that delivers peace of mind and unlocks business value with unique solutions to complex commercial problems. With more than 15 years of dedicated life sciences experience, its worldwide team of experts provides insights and solves problems in contracting, pricing, reimbursement, and commercial operations. Alliance serves top pharmaceutical manufacturers, mid-market life sciences companies, and multiple medical device and diagnostic firms. For more information, visit www.alscg.com.
About Health Strategies Group
Health Strategies Group offers a dedicated team of research leaders committed to dissecting the trends, identifying customer needs, and pinpointing the barriers and opportunities for biopharma within the evolving health care environment. Recently, Health Strategies Group was ranked the No. 1 market research company that pharmaceutical and biotech executives would recommend for market access insights. For more information, visit healthstrategies.com.
About The Access Group
The Access Group—named a top 100 agency by MM&M five years in a row—offers a breadth of services to clients, from traditional “block-and-tackle” launch execution tactics to in-depth market assessments. The company is dedicated to complete product life cycle management—from prelaunch to loss of exclusivity—creating strategic brand solutions that drive demand across multiple stakeholder channels. The Access Group is committed to delivering strategic and tactical solutions that help companies overcome internal and external hurdles in the constantly evolving health care environment. For more information, visit http://theaccessgp.com.
About Water Street
Water Street is a strategic investor focused exclusively on health care. The firm has a strong record of building market-leading companies across key growth sectors in health care. It has worked with some of the world’s leading health care companies on its investments including Johnson & Johnson, Medtronic, Smith & Nephew and Walgreen Co. Water Street’s team is comprised of industry executives and investment professionals with decades of experience investing in and operating global health care businesses. The firm is headquartered in Chicago. For more information about Water Street, visit waterstreet.com.
+1 847 858 5230
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
American Airlines Announces Nonstop Philadelphia (PHL) to Orlando Melbourne (MLB)22.9.2018 01:13 | Tiedote
Glorious beaches by day and theme park fireworks by night just got more convenient for Philadelphia travelers. American Airlines announced today that it will begin nonstop flights to Orlando Melbourne International Airport (MLB) starting February 16, 2019. The Central Florida airport is conveniently located in the heart of the tourism region and is the closest airport to NASA rocket launches, Port Canaveral’s cruises and what critics call “some of the most beautiful beaches Florida has to offer.” The flights will depart Saturdays from Philadelphia at 8:05 a.m., arriving in Florida at 10:48 a.m. The Embraer 175 jet arrival time syncs perfectly with cruise ship noon early boarding. Melbourne Airport Express offers nonstop shuttle service to the port, and all major rental car companies are onsite. The return flight to PHL departs at 11:24 a.m. and arrives in PHL at 1:55 p.m., with enough time to connect to some of American’s largest international destinations, including recently announced
Amy Palladino Joins BCW as Executive Vice President, Managing Director, Corporate Practice21.9.2018 20:43 | Tiedote
BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced that Amy Palladino has joined the agency as Executive Vice President, Managing Director in the agency’s U.S. Corporate Practice. Based in New York, Palladino will focus on senior client counsel and executive positioning for the agency’s largest corporate clients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005507/en/ Amy Palladino Joins BCW (Burson Cohn & Wolfe) “Amy is a talented and highly experienced communications executive with a track record of solving clients’ complex challenges and building business through smart, integrated communications approaches,” said Chris Foster, President, North America, BCW. “Her creativity and judgement will be enormously valuable to our current and prospective clients.” Palladino has more than 20 years of experience advising global clients across numerous industries, including technology, healthcar
Heidelberg Engineering Announces the CE-Marking of ANTERION21.9.2018 19:41 | Tiedote
Heidelberg Engineering, the leader in diagnostic imaging known for the internationally-acclaimed SPECTRALIS ® retina and glaucoma platform, announces the CE-marking of ANTERION ® – an innovative platform designed to transform anterior segment diagnostics and workflow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005442/en/ The new Heidelberg Engineering ANTERION® provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. (Graphic: Business Wire) The new ANTERION provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. It is a single, workflow-efficient solution that brings together corneal topography and tomography, anterior segment metrics, axial length measurement and IOL calculation to transform the day-to-day routine of busy practices and clinics. Heidelberg Engineering has leveraged its core OCT technolo
Florian Winterstein Becomes New CEO of Jedox21.9.2018 18:46 | Tiedote
The supervisory board of Jedox AG, a leading vendor of business intelligence and enterprise planning software, has appointed Florian Winterstein as Chief Executive Officer (CEO) effective October 2, 2018. This nomination will support Jedox’s international growth and a new development phase initiated by its latest fund raising in April 2018 with Iris Capital, eCAPITAL entrepreneurial Partners AG and Wecken & Cie. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005416/en/ Florian Winterstein (Photo: Business Wire) With 25 years of experience in strategy consulting and leadership in software and service organizations, Winterstein brings to the company a valuable combination of expertise in cloud solutions, business development, and value creation for customers and partners. As former Chief Strategy Officer of BravoSolution, he positioned the software-as-a-service company as trendsetting digitalization partner, extending it
Avinor to Test Autonomous Snowploughs at Oslo Airport This Winter21.9.2018 17:37 | Tiedote
Since 2010 Avinor has had a vision and a desire to automate winter maintenance. In March autonomous snow clearing was demonstrated at Fagernes Airport, and this winter Avinor is taking this a step further by testing two autonomous snowploughs at Oslo Airport. The project is one of the first globally where large machinery will operate autonomously to keep snow away from airport areas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005363/en/ Avinor to Test Autonomous Snowploughs at Oslo Airport This Winter (Photo: Business Wire) “Innovation is important to Avinor. In the future, many tasks in aviation will be resolved in other ways than today. Avinor wants to test autonomy, and does of course see a potential for rationalization in the future through new solutions for winter operations and in other areas. Avinor is at the forefront of testing this technology, but it is essential that safety is ensured in all such testing
Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib21.9.2018 16:30 | Tiedote
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full approval of ALUNBRIG® (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. ALUNBRIG is a tyrosine kinase inhibitor (TKI) designed to target and inhibit the ALK mutation in NSCLC. Approximately three to five percent of NSCLC patients globally have the ALK mutation. If the CHMP opinion is affirmed, and the European Commission approves ALUNBRIG, it will become the only ALK inhibitor available in the European Union as a one tablet per day dose that can be taken with or without food. The randomized, global Phase 2 ALTA trial was designed to investigate the efficacy and safety of ALUNBRIG in patients with locally advanced or metastatic ALK+
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme